With the latest approval of Zynteglo, Skysona and Hemgenix, are $3M+ gene therapies the new normal?
For all the potential of gene therapy, treatment prices are proving extremely challenging for health plans, who are wondering -
Quantile Pipeline Analytics answers these important questions, with real time pipeline and cost projections, in one source-of-truth portal.Contact us to learn more
A real-time payer budgeting tool that will inform you when each gene therapy will be approved, at what price, and how much it will cost for your risk pool for the next 5 years.
Tracks all late-stage gene and cell therapy pipeline with cost estimates, and notifies you of any upcoming approvals
Estimates the per-member-per-month (PMPM) gene and cell therapy spending, by year, state, and line of business (i.e. Medicaid, Employer etc.)
Dives into the drug level breakdown to help health plans make more informed budgeting and coverage decisions
Custom services are available, including cost forecasts specific to your own member history, analysis of drug clinical benefit, etc.